Physician profile
Steven E Speights
NPI 1790722999
$44,759.98
in general payments reported to CMS, 2019-2025
27 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 77% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $24K · 2021: $2,458 · 2022: $839 · 2023: $754 · 2024: $672 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Travel and Lodging: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.33 |
| Travel and Lodging | $686.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $37,351.42 | 2019-2021 | |
| Axonics, INC. | $4,029.29 | 2020-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $1,429.08 | 2019-2025 | Solyx Sis System, Axonics, Bulkamid |
| Medtronic USA, INC. | $348.57 | 2019-2020 | |
| Astellas Pharma US INC | $346.34 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $304.71 | 2023-2025 | Gemtesa, Myfembree |
| Allergan, INC. | $281.85 | 2019-2021 | |
| Abbvie INC. | $98.19 | 2021-2025 | Botox |
| Intuitive Surgical, INC. | $84.91 | 2024 | |
| Eisai INC. | $67.38 | 2021 | |
| Coloplast Corp | $55.10 | 2019-2023 | Saffron |
| Therapeuticsmd, INC. | $54.76 | 2019-2020 | |
| Rochester Medical Corporation | $37.81 | 2019 | |
| Currax Pharmaceuticals LLC | $32.98 | 2022-2025 | Onzetra Xsail, Contrave |
| Hologic Sales and Service, LLC | $25.59 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $23.26 | 2025 | Irrisept |
| Medtronic, INC. | $23.06 | 2021 | |
| Tolmar, INC. | $21.93 | 2025 | Jatenzo |
| Provepharm INC. | $21.14 | 2025 | Bludigo |
| Medline Industries LP | $20.61 | 2023 | |
| Myovant Sciences INC. | $17.47 | 2021 | |
| Kedrion Biopharma, INC. | $16.55 | 2024 | Kedrab, Gammaked, Koate |
| Mission Pharmacal Company | $16.04 | 2022 | |
| Hollister Incorporated | $15.31 | 2022 | |
| Pfizer INC. | $12.84 | 2020 | |
| Mayne Pharma Commercial LLC | $12.05 | 2024 | |
| Acerus Pharmaceuticals Corporation | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Speights listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.